Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Core Viewpoint - Savara Inc. has received a new patent from the European Patent Office for its investigational therapy MOLBREEVI, which is a significant development in the treatment of rare respiratory diseases [1] Group 1: Patent Announcement - The European Patent Office has issued patent No. 4 496 611 titled "Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution" [1] - The patent is jointly held by Savara and PARI, indicating a collaboration between the two companies [1] - The patent covers the combination of Savara's investigational therapy MOLBREEVI and PARI's investigational device [1]